December 12, 2016
Novartis combination against age-related vision loss fails tests
Novartis was denied bringing its eye drug combination of pegpleranib and Lucentis out of Phase III study for age-related vision…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
December 9, 2016
Valneva to test its Lyme disease vaccine
Valneva said on Friday it will sent its Lyme disease vaccine candidate VLA15 to clinic. Phase I testing can begin…
December 9, 2016
Allergan dissapointed with PTAB’s reaction as Mylan petitions for IPR of Restasis patents
Allergan said on Thursday that it was disappointed in the PTAB’s decision to institute IPR proceedings regarding the patents that…
December 8, 2016
Horizon quits Friedreich’s ataxia treatment study
Horizon Pharma has announced that the Phase 3 trial, Steadfast (Safety, Tolerability and Efficacy of Actimmune Dose Escalation in Friedreich’s Ataxia study), evaluating Actimmune (interferon gamma-1b) for…
December 8, 2016
EMA to review Sanofi/Regeneron’s skin disease treatment Dupixent
Sanofi and Regeneron Pharmaceuticals have announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application…
December 8, 2016
Erytech places shares, funds acute leukemia drug
Acute leukemia focused pharmaceutical company Erytech Pharma, has announced the closing of a private placement of 793,877 ordinary shares to…
December 8, 2016
ValiRx’s prostate cancer drug gets European patent
European Patent Office has granted ValiRx’s patent covering its major therapeutic compound VAL201, including prostate cancer, the pharmaceutical company said on…
December 8, 2016
Hair care company places shares, raises half million
InnovaDerma, a UK -based company focused on hair loss, hair care, self-tanning and skin rejuvenation, has raised £539,999.60 through the…
December 8, 2016
Bayer buys BIVI’s animal health products in US
Bayer and Boehringer Ingelheim Vetmedica, Inc. (BIVI) have made a deal for Bayer to buy BIVI’s Cydectin bovine and ovine…
December 7, 2016
Biocartis launches second liquid biopsy assay
Biocartis Group NV has launched its second liquid biopsy assay, the Idylla ctKRAS Mutation Assay, which was developed in partnership…